Arecor Therapeutics PLC
AREC.L is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and commercialization of diagnostic products and services.
Business. AREC.L is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm generates revenue through a product-sale model, focusing on the development and commercialization of diagnostic solutions. It is primarily listed on the London Stock Exchange under the ticker AREC.L. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Analyst recommendations
2 analysts · consensus Buy- DividendDividend USD 0.0431/sh2026-08-25
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- DividendDividend USD 0.0431/sh2026-08-25
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
AREC.L is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm generates revenue through a product-sale model, focusing on the development and commercialization of diagnostic solutions. It is primarily listed on the London Stock Exchange under the ticker AREC.L. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
AREC.L maintains a strong liquidity position with a current ratio of 4.78, indicating the company can easily cover its short-term liabilities with its short-term assets. However, the company reported negative operating cash flow of -2.363 million GBP, which contrasts with a positive free cash flow of 1.048 million GBP, suggesting that capital expenditures are being managed effectively.
Profitability metrics show a return on equity of 10.29% and a return on assets of 8.2%, both of which are strong indicators of efficient use of equity and assets. The company's gross profit of 1.266 million GBP and operating income of 0.932 million GBP reflect a healthy margin structure, although these figures should be compared to industry medians to assess relative performance.
Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. However, the company operates in the healthcare diagnostics space, which is typically less sensitive to geographic volatility compared to other industries. The lack of segment-specific revenue data limits the ability to assess exposure to different markets or product lines.
Looking ahead, the company is projected to maintain a stable revenue trajectory, with no significant growth or decline expected in the next fiscal year. The current fiscal year's revenue of 1.714 million GBP provides a baseline for future performance, and the absence of significant capital expenditures suggests a conservative approach to growth.
Risk factors include a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no immediate pressure from share issuance or other dilutive events. The company's debt-to-equity ratio of 0.02 indicates a conservative capital structure, reducing financial leverage risk.
Recent events include analyst estimates that suggest a mean price target of 275.50 GBP, with a median of 275.50 GBP and a range from 251.00 GBP to 300.00 GBP. The mean recommendation of 1.50 indicates a generally positive outlook from analysts, with one strong-buy and one buy rating reported.
- AREC.L has a strong liquidity position with a current ratio of 4.78, but it faces a negative operating cash flow of -2.363 million GBP.
- The company's return on equity of 10.29% and return on assets of 8.2% indicate efficient use of equity and assets.
- The company's capital structure is conservative, with a low debt-to-equity ratio of 0.02.
- Analysts have a generally positive outlook, with a mean price target of 275.50 GBP and a mean recommendation of 1.50.
- The company's revenue concentration and segment-specific data are not disclosed, limiting the ability to assess geographic or product line exposure.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,00 |
| Revenue | —no estimate | —no estimate | 900,000 GBP |
| Operating income | —no estimate | —no estimate | -6,0M GBP |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- AREC.L Market data — financials · 2026-05-27
- Arecor Therapeutics PLC Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Sarah Jennifer HowellChief Executive Officer, Executive Director
Insider activity
- 10% owner · Class A Common StockSold 10 000 @ $4,02$40K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,07$41K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,06$41K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,08$41K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,10$41K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,09$41K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,11$41K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,12$41K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,13$41K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,16$42K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,14$41K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,22$42K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,23$42K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,21$42K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,15$42K · 2025-11-10
- 10% owner · Class A Common StockSold 20 000 @ $4,01$80K · 2025-11-10
- 10% owner · Class A Common StockSold 20 000 @ $4,00$80K · 2025-11-10
- 10% owner · Class A Common StockSold 20 000 @ $4,02$80K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,00$40K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,01$40K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,03$40K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,04$40K · 2025-11-10
- 10% owner · Class A Common StockSold 20 000 @ $4,07$81K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,06$41K · 2025-11-10
- 10% owner · Class A Common StockSold 10 000 @ $4,05$40K · 2025-11-10
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 219.4%Derived (calculated)
- Return on equity (FY 2025-12-31): 58.4%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -40.0%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -79.1%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 15,636.4%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 223.5%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 241.3%Derived (calculated)
- Return on assets (FY 2025-12-31): 32.8%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.80xDerived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 20.5%Derived (calculated)
- Current ratio (FY 2025-12-31): 2.19xDerived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -100.0%Derived (calculated)
- Current liabilities (annual): USD 61.21MSEC XBRL filing
- Total assets (annual): USD 168.91MSEC XBRL filing
- Shares outstanding (annual): 106.92MSEC XBRL filing
- Shareholders' equity (annual): USD 94.78MSEC XBRL filing
- Net income (annual): USD 55.39MSEC XBRL filing
- Total operating expenses (annual): USD 11.31MSEC XBRL filing
- Total liabilities (annual): USD 75.72MSEC XBRL filing
- Cash & equivalents (annual): USD 31.7MSEC XBRL filing
- Pre-tax income (annual): USD -17.83MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 1SEC XBRL filing
- Long-term debt (annual): USD 965.29KSEC XBRL filing
- Current assets (annual): USD 134.26MSEC XBRL filing